Related Experiment Video
Updated: Jul 6, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Prostate transmembrane androgen inducible protein 1 (PMEPA1): regulation and clinical implications
Qicui Zhu1, Yue Wang1, Yaqian Liu1
1Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Abstract:
Prostate transmembrane androgen inducible protein 1 (PMEPA1) can promote or inhibit prostate cancer cell growth based on the cancer cell response to the androgen receptor (AR). Further, it can be upregulated by transforming growth factor (TGF), which downregulates transforming growth factor-β (TGF-β) signaling by interfering with R-Smad phosphorylation to facilitate TGF-β receptor degradation. Studies have indicated the increased expression of PMEPA1 in some solid tumors and its functioning as a regulator of multiple signaling pathways. This review highlights the multiple potential signaling pathways associated with PMEPA1 and the role of the PMEPA1 gene in regulating prognosis, including transcriptional regulation and epithelial mesenchymal transition (EMT). Moreover, the relevant implications in and outside tumors, for example, as a biomarker and its potential functions in lysosomes have also been discussed.
More Related Videos
Related Concept Videos
Master Transcription Regulators
cAMP-dependent Protein Kinase Pathways
Regulation of Angiogenesis and Blood Supply
GPCRs Regulate Adenylyl Cylase Activity
Abnormal Proliferation
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

